<DOC>
	<DOCNO>NCT02953106</DOCNO>
	<brief_summary>Single centre , double-blind , placebo control , adaptive design , cross-over trial . The primary objective ass additive effect use combine intranasal fluticasone propionate plus azelastine nasal spray airway hyperresponsiveness . This patient persistent asthma allergic rhinitis , receive inhale steroid .</brief_summary>
	<brief_title>Assessing Effects Intranasal Fluticasone Plus Azelastine Airway Inflammation Patients With Asthma Allergic Rhinitis</brief_title>
	<detailed_description>The unified allergic airway describe patient asthma allergic rhinitis . Both condition similar underlie pathophysiology term T-helper 2 ( Th2 ) cell activation . Patients unified allergic airway disease great burden term impaired quality life , presence airway hyper-responsiveness ( AHR ) methacholine hallmark underlie asthmatic inflammatory process . Targeting Th2 allergic airway topical antihistamine may improve airway hyperresponsiveness . It previously show patient unified allergic airway disease , use inhaled fluticasone alone ( 100 microgram per day ) produce 1.2 double dilution ( dd ) shift provocative concentration methacholine require reduce forced expiratory volume ( FEV1 ) 20 % ( PC20 ) . However add nasal fluticasone inhale steroid , 1.79 dd shift . This difference ( 0.58 dd , 95 % CI 0.78 , 1.95 ) statistically significant . However combine treatment result significant improvement rhinitis quality life , nasal inflammation inspiratory flow . The investigator repeat previous concept , compare intranasal fluticasone azelastine ( antihistamine ) nasal spray versus placebo nasal spray , atopic asthmatic patient inhale steroid . This assess effect methacholine PC20 , primary outcome , assess effect follow secondary outcome : Exhaled nitric oxide ( FeNO ) , FEV1 , morning peak expiratory flow ( PEF ) , impulse oscillometry , peak nasal inspiratory flow ( PNIF ) , nasal nitric oxide ( NO ) , blood eosinophil , eosinophilic cationic protein ( ECP ) , nasal symptom , asthma control quality life ; rhinitis quality life . Twenty adult 18 , allergic asthma enrol . They run-in 2 week 200 microgram beclometasone inhaler randomise add either intranasal fluticasone azelastine , placebo nasal spray treatment ( double blind ) . Treatment period one 3-5 week follow washout 2-4 week , crossover treatment period two 3-5 week . Due crossover nature study participant receive treatment random order . There Interim analysis 20 participant complete study per protocol exact require sample size recalculate ( Pocock/adaptive design ) .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Azelastine</mesh_term>
	<criteria>Male female volunteer , age 18 year , persistent asthma allergic rhinitis On minimum 200μg BDP Inhaled corticosteroid ( ICS ) FEV1 ≥ 60 % predict Positive skin prick test , record elevate allergenspecific IgE least 1 perennial allergen Methacholine PC20 &lt; 8mg/ml Visit 1 Ability give inform consent Other respiratory disease COPD , bronchiectasis allergic bronchopulmonary aspergillosis ( ABPA ) consider significant opinion study physician Nasal polyp ≥ Grade 2 An asthma exacerbation respiratory tract infection require systemic steroid and/or antibiotic within 1 month study commencement , 3 month hospital admission require Any clinically significant medical condition may endanger health safety participant . For example : Patients tuberculosis type untreated infection recent surgical operation injury nose mouth . Participation another trial within 30 day commencement study Pregnancy lactation Unable comply procedure protocol Unable unwilling consent Taking prohibit medication list section 6.7.2 Prohibited Medications Hypersensitivity active substance excipients Dymista Nasal Spray .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Rhinitis</keyword>
	<keyword>Dymista</keyword>
	<keyword>allergy</keyword>
</DOC>